Theravance Inc reports 2Q 2010 Financial Results.(Financial report)

Theravance Inc (Theravance) registered its financial results for the 2Q and 1H ended 30 Jun 2010. Revenue for the 2Q and 1H 2010 was $6.264 M and $11.979 M ($5.493 M in 2Q and $15.037 M in 1H 2009). Net loss for the 2Q of 2010 was $20.8 M or $0.28/share ($21.692 M or $0.35/share in 2Q 2009). Net loss for 1H 2010 was $43.341 M or $0.63/share in 2010($40.909 M or $0.65/share in 1H 2009). In Mar 2010, GlaxoSmithKline and Theravance announced that the first asthma patient commenced treatment with Relovair (fluticasone furoate/vilanterol trifenatate) in an asthma exacerbation study, marking the start of the III asthma clinical development programme with this once-daily therapy. Enrolment is …